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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal, neurodegenerative disease that is characterized by the selective
degeneration of upper motor neurons and lower spinal motor neurons, resulting in the progressive paralysis of all
voluntary muscles. Approximately 10 % of ALS cases are linked to known genetic mutations, with the remaining 90 %
of cases being sporadic. While the primary pathology in ALS is the selective death of upper and lower motor neurons,
numerous studies indicate that an imbalance in whole body and/or cellular metabolism influences the rate of
progression of disease. This review summarizes current research surrounding the impact of impaired metabolic
physiology in ALS. We extend ideas to consider prospects that lie ahead in terms of how metabolic alterations may
impact the selective degeneration of neurons in ALS and how targeting of adenosine triphosphate-sensitive potassium
(KATP) channels may represent a promising approach for obtaining neuroprotection in ALS.
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Introduction
Amyotrophic lateral sclerosis (ALS) is the most common
form of motor neuron disease, initially described in 1869
by Jean-Martin Charcot [1]. ALS is a fatal, neurodegen-
erative disease in which the primary hallmark is the
selective degeneration of upper motor neurons and
lower spinal motor neurons. The loss of these motor
neurons results in progressive paralysis of all voluntary
muscles [2]. The underlying cause for ALS remains
unknown, although many hypotheses to explain the
selective death of upper and lower motor neurons have
been proposed. Causative theories include abnormal pro-
tein function and RNA processing [3–7], mitochondrial
dysfunction [8], non-cell autonomous death [9, 10], hyper-
excitability [11, 12], excitotoxicity [13], and metabolic dys-
function [14]. Despite these theories, it is unlikely that
ALS is caused by or results from any single one of these
processes.
Approximately 10 % of ALS is defined as being familial,
and the remaining 90 % of cases are considered sporadic,
[15, 16]. Mutations in a number of genes including
C9orf72 [4, 7], SOD1 [17], TARDBP [5, 18], and FUS
[19, 20] cause familial ALS and contribute to sporadic
ALS (reviewed in [15]). Interestingly, in line with the
multifactorial nature of ALS, a recent modelling study by
Al-Chalabi and colleagues suggests that in ALS, an under-
lying genetic susceptibility occurs in combination with en-
vironmental factors, which culminates in up to six
exposures with the final exposure triggering the onset of
disease [21]. Potential environmental risk factors that have
been proposed to contribute to ALS include elite athleti-
cism [22–24], β-methylamino-L-alanine (BMAA) [25, 26],
pesticides [27, 28], and lifestyle factors (including smoking
[29, 30], diet [31–35], and body mass index [36–41])
amongst many others (reviewed in [42]).
Evidence of metabolic dysfunction in ALS was re-
ported throughout the 1970s and 1980s [43, 44]. Since
that time, investigation into the contribution of the
* Correspondence: s.ngo@uq.edu.au
1Queensland Brain Institute, The University of Queensland, St Lucia, Brisbane
4072, Australia
2School of Biomedical Sciences, The University of Queensland, St Lucia,
Brisbane 4072, Australia
Full list of author information is available at the end of the article
© 2015 Ngo and Steyn. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in
this article, unless otherwise stated.
Ngo and Steyn Cell Regeneration  (2015) 4:5 
DOI 10.1186/s13619-015-0019-6
dysregulation in metabolic homeostasis to the patho-
genesis of ALS has increased significantly. Numerous
studies now indicate that ALS patients have impair-
ments in whole body physiology and energy homeosta-
sis, with data suggesting that an imbalance in energy
metabolism appears to negatively influence the rate of
progression of disease [14, 36–38, 40, 41, 45–62].
Should this be the case, attempts to offset energy defi-
cits (e.g. through careful nutritional management [63])
to improve prognosis must take the metabolic state and
underlying cause of metabolic perturbations of the per-
son living with ALS into consideration. This review will
focus on current research investigating the impact of
impaired metabolic physiology in ALS and will consider
prospects that lie ahead in terms of how metabolic al-
terations may impact the selective death of neurons in
ALS.
Metabolic homeostasis: the complex nature of
balancing energy intake with energy expenditure
Metabolic homoeostasis and body composition requires
balancing energy intake with energy expenditure. Seem-
ingly simple in theory, the practical underpinnings of
maintaining metabolic balance extend well beyond nutri-
ent intake and absorption and resting metabolism and
physical activity. Many fundamental regulators of meta-
bolic physiology reside within the endocrine and neuro-
endocrine systems of the body. For example, orexigenic
and anorexigenic neurons in the hypothalamus secrete
neuropeptides that stimulate and inhibit appetite, re-
spectively (reviewed in [64]), hormones secreted from
the stomach and adipose control appetite (reviewed in
[65]), pituitary-derived (e.g. growth hormone) and pan-
creatic hormones (e.g. insulin) play vital roles in modu-
lating insulin action, glucose metabolism, free fatty acid
flux, and body composition (reviewed in [66]), and the
interplay between the neuroendocrine and endocrine
systems can greatly influence physiological responses
during periods of both positive and negative energy bal-
ance (reviewed in [67]). Not surprisingly, perturbation to
endocrine and neuroendocrine processes typically results
in the development of metabolic complications as is seen
in type 2 diabetes and metabolic syndrome.
Dysregulation of metabolic homeostasis in ALS:
causes and consequences
In ALS patients, growth hormone deficiency [68], glucose
intolerance [61], insulin resistance [43], hyperlipidemia
[69], hypometabolism [46, 70–72], hypermetabolism
[47, 48, 54, 72], and reduced body mass index (BMI)
throughout the course of disease [36, 37, 41, 57, 59] are
telling signs of the existence and progressive worsening
of dysregulated metabolic homeostasis. These observa-
tions have sparked attempts to identify the underlying
cause and the consequences of metabolic perturbations
in ALS.
ALS-causing genes and metabolism
The underlying cause of defective metabolic homeostasis
in ALS remains to be fully determined. Mutations in or
altered expression of ALS-associated genes in mice, cell
lines, and humans are often coupled with metabolic ab-
normalities. In mice expressing SOD1G86R or SOD1G93A
mutations, hypermetabolism and defects in glucose
metabolism are observed [14, 60]. Deletion of TARDP
(TDP-43) in adult mice results in weight loss, depletion
of fat mass, and rapid death [73]. By contrast, overex-
pression of TDP-43 in mice (TDP-43A315T) results in
increased fat deposition and hypertrophy of adipocytes
[74]. When overexpressed in mouse skeletal muscle,
TDP-43 drives an increase in the steady state expression
of Tbc1d1, a Rab-GTPase-activating protein. Increased
Tbc1d1 expression is thought to reduce insulin-stimulated
translocation of the Glut4 transporter from tubulovesicu-
lar structures adjacent to the Golgi complex and from ves-
icles throughout the cytoplasm to the cell surface,
impairing insulin-mediated glucose uptake [74]. Moreover,
overexpression of human TDP-43 in mice underpins mor-
phological abnormalities during mitochondrial formation
[75, 76]. When considering FUS mutations, mass spec-
trometry analysis of protein interactions in HEK293 cells
overexpressing mutant FUS associated with juvenile ALS
demonstrate greater interactions with mitochondrial en-
zymes and proteins involved in glucose metabolism [77].
Not surprisingly, exogenous expression of mutant FUS in
HEK293 and SH-SY5Y cells leads to a significant reduc-
tion in cellular adenosine triphosphate (ATP) production
[77]. Finally, humans with ALS who harbour the C9orf72
repeat expansion exhibit hypometabolism in numerous
brain regions when compared to sporadic ALS patients
[70]. Collectively, results indicate that the expression of
ALS-associated genes SOD1, TARDP, FUS, and C9orf72 is
tightly linked to processes that are involved in regulating
lipid and glucose homeostasis, mitochondrial forma-
tion, and ATP production. The presentation of meta-
bolic defects in parallel with ALS-causing gene
mutations point to the possible existence of a genetic
predisposition to metabolic abnormalities in ALS and
suggest a potential integral role for metabolic factors in
regulating the progression and development of ALS.
Targets of dysregulated metabolic homeostasis in
ALS: the endocrine organs
Pristine physiological responses that occur throughout the
body in response to metabolic pressures serve to ensure
optimal metabolic flux. In turn, this sustains favourable
responses to the metabolic demands of disease, thereby
enhancing the likelihood for survival. Interestingly, altered
Ngo and Steyn Cell Regeneration  (2015) 4:5 Page 2 of 14
metabolic homeostasis in ALS presents at the whole
body level, and some of the targets that are affected in
ALS are major endocrine organs that play crucial roles
in regulating glucose and free fatty acid flux. We will
briefly consider the adipose tissue, liver and muscle as
critical metabolic organs that modulate homeostatic
responses during the progression of ALS.
Adipose
Adipose triglycerides represent the largest energy reserve
in the human body. Within all cell types, triacylglycerols
are stored as cytoplasmic lipid droplets or fat droplets that
are enclosed by a monolayer of phospholipids and hydro-
phobic proteins. Fatty acids that arise from the breakdown
of triacylglycerols play crucial roles in membrane biosyn-
thesis, signal transduction, and energy production. Im-
portantly, fatty acids that are derived from adipocyte
triacylglycerols and released into circulation are in general,
the primary regulators of fatty acid metabolism. Thus, in
normal physiology, the maintenance of metabolic homeo-
stasis is critically dependent on the flux between the
uptake and storage of lipids (lipogenesis) during periods of
positive energy balance and the breakdown and release of
lipids (lipolysis) from adipocytes during periods of nega-
tive energy balance (reviewed in [78]).
It was first noted in the 1970s that ALS patients have
larger subcutaneous fat cells [44], and it has been sug-
gested that defects in carbohydrate metabolism and
increased serum triglycerides in ALS patients might be
somewhat related to this enlargement of subcutaneous
fat cells. More recently, increased expression of a num-
ber of fat-derived cytokines (adipokines) that are associ-
ated with metabolic disease has been observed in ALS
patients [79]. While the significance of these changes re-
mains to be defined, there is evidence to show that the
regulation of lipolytic processes to maintain metabolic
flux could be key to promoting a survival advantage in
ALS. In 2008, Dupuis et al. presented evidence to show
that increased low-density lipoprotein:high-density lipo-
protein ratio was associated with extended survival in
ALS [69]. Subsequent to this, elevated serum triglycer-
ides [51], higher palmitoleate and blood cell palmitolea-
te:palmitate ratio [80], and higher BMI (commonly used
as a measure of increased body “fatness”) have been
linked to improved survival in ALS [36, 37, 41, 57–59].
Moreover, Lindauer and colleagues have demonstrated a
favourable relationship between subcutaneous adiposity
and survival in ALS patients [81]. Thus, current studies
suggest that the availability and mobilization of lipids
from larger subcutaneous adipose stores into circulation
may play a fundamental role in modulating the course of
disease. In this regard, a greater capacity to mobilize
lipids may favourably impact disease progression. The
mechanisms by which increased fat mass or increased
movement of lipids into circulation exerts beneficial ef-
fects in ALS remain to be determined, but it is plausible
that the availability of excess fatty acids may assist in the
provision of an alternative metabolic substrate to meet
energy demand in ALS.
Liver
The liver is an essential endocrine organ that regulates
lipogenesis, gluconeogenesis, and cholesterol metabol-
ism; it is a major site at which carbohydrates, proteins,
and lipids are synthesized, metabolized, stored, and
redistributed. Under fed states, the liver stores glycogen
and triglyceride (which is later redistributed to adipose).
In the fasted state, the liver releases glucose (formed via
gluconeogenesis) and ketone bodies (produced from
fatty acids). Influenced by glucose, insulin, and glucagon,
liver carbohydrate and fatty acid metabolism orient
metabolic fluxes towards energy storage or substrate re-
lease (reviewed in [82]).
Ultrastructural abnormalities in the liver [83–86], fatty
acid infiltration into the liver [86], and mild liver dys-
function have been observed in ALS patients [86]. More
recently, hepatic steatosis has been reported to be a fre-
quent occurrence in ALS [69, 87]. While the discussions
surrounding the prognostic and metabolic implications
of hepatic steatosis in ALS remain open, abnormal
insulin-like growth factor-1 (IGF-1) axis function along-
side lipid redistribution in SOD1G93A mice [88], and dys-
regulation of lipid metabolism in response to genetic
ablation of TDP-43 in mice [73] provide a foundation
upon which the beneficial effects of altered hepatic lipid
metabolism in ALS can be explored.
Skeletal muscle
Skeletal muscle is a major consumer of glucose and thus
plays a fundamental role in the maintenance of glucose
homeostasis and carbohydrate metabolism. Skeletal
muscle is dependent upon small quantities of blood glu-
cose during periods of rest or fasting. However, after in-
sulin stimulation, the need for blood glucose in the
skeletal muscle increases to approximately 75 % of that
required by the body [89, 90]. Given its metabolically de-
manding nature, it has been proposed that metabolic de-
fects in ALS originate from the skeletal muscle [91]. In
support of this, muscle-restricted expression of the
superoxide dismutase 1 (SOD1) gene causes muscle at-
rophy via oxidative damage and mitochondrial dysfunc-
tion [91, 92], and muscle restricted mitochondrial
dysfunction drives motor neuron degeneration [93].
Moreover, in ALS skeletal muscle, structural and func-
tional abnormalities in mitochondria [94–96], impaired
glucose use and oxidative mitochondrial metabolism
[60, 97–100], defective activity of respiratory complexes
I and IV [95, 96, 101], and reduced cellular ATP [97]
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exist. More recently, using the SOD1G86R mouse model of
ALS, Palamuic and colleagues demonstrate that skeletal
muscle mitochondrial dysfunction and denervation in
ALS likely occurs due to a decreased ability to generate
energy via glucose metabolism [60]. Consistent with this,
our analysis of the skeletal muscle from the SOD1G93A
mouse model of ALS (B6.Cg-Tg(SOD1-G93A)1Gur/J; all
SOD1G93A mice had ≥ 25 copies of the SOD1 gene) using
a mouse Glucose Metabolism RT2 Profiler PCR Array
(PAMM-006Z, QIAGEN, Germany, strictly adhering to
supplied protocols and guidelines) illustrate altered
expression of a number of genes critically involved in the
processes that regulate muscle glucose metabolism (listed
in Table 1), starting at disease onset (8 weeks of age) and
continuing through to mid-stage (18 weeks of age) and
end-stage (24 weeks of age) of disease (Fig. 1). Compared
to non-transgenic littermate control mice, we observed a
marked decrease in genes central to all processes that are
associated with glucose metabolism (including glycolysis,
tricarboxylic acid (TCA) cycle, gluconeogenesis, and glu-
cose regulation) and glycogen metabolism (including
glycogen synthesis, regulation, and degradation). We
Table 1 Gene descriptions and identifiers for data described in Fig. 1
Symbol Description Gene symbol UniGene identifier NCBI
RefSeq
Aco1 Aconitase 1 AI256519, Aco-1, Irebp, Irp1 Mm.331547 NM_007386
Aco2 Aconitase 2, mitochondrial Aco-2, Aco3, D10Wsu183e Mm.154581 NM_080633
Aldob Aldolase B, fructose-bisphosphate Aldo-2, Aldo2, BC016435, MGC36398 Mm.482116 NM_144903
Bpgm 2,3-Bisphosphoglycerate mutase AI323730, AL022789, C86192 Mm.28263 NM_007563
Dld Dihydrolipoamide dehydrogenase AI315664, AI746344 Mm.3131 NM_007861
Eno1 Enolase 1, alpha non-neuron 0610008l15, AL022784, Eno-1, MBP-1,
MGC103111, MGC107267
Mm.70666 NM_023119
Eno3 Enolase 3, beta muscle Eno-3 Mm.251322 NM_007933
Gbe1 Glucan (1,4-alpha-), branching enzyme 1 2310045H19Rik, 2810426P10Rik, D16Ertd536e Mm.396102 NM_028803
Gys1 Glycogen synthase 1, muscle Gys3, MGS Mm.275654 NM_030678
Gys2 Glycogen synthase 2 BC021322, LGS, MGC29379 Mm.275975 NM_145572
Idh1 Isocitrate dehydrogenase 1 (NADP+), soluble AI31485, AI788952, E030024J03Rik, Id-1, Idh-1,
Idpc, MGC115782
Mm.9925 NM_010497
Idh2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial E430004F23, IDPm, Idh-2 Mm.246432 NM_173011
Mdh1 Malate dehydrogenase 1, NAD (soluble) B230377B03Rik, D17921, MDH-s, MDHA,
Mor-2, Mor2
Mm.212703 NM_008618
Mdh1b Malate dehydrogenase 1B, NAD (soluble) 1700124B08Rik, AV255588 Mm.30494 NM-029696
Pck1 Phosphoenolpyruvate carboxykinase 1, cytosolic AI265463. PEPCK, Pck-1 Mm.266867 NM_011044
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 AV005916 Mm.235547 NM_013743
Pgk1 Phosphoglycerate kinase 1 MGC118097, Pgk-1 Mm.336205 NM_008823
Phka1 Phosphorylase kinase alpha 1 5330411D17, 9830108K24Rik, Phka Mm.212889 NM_173021
Phkb Phosphorylase kinase beta AI462371, MGC62514 Mm.237296 NM_199446
Phkg1 Phosphorylase kinase gamma 1 Phkg Mm.3159 NM_011079
Pygm Muscle glycogen phosphorylase AI115133, PG Mm.27806 NM_011224
Sdha Succinate dehydrogenase complex, subunit A,
flavoprotein (Fp)
1500032O14Rik, 2310034D06Rik, 4921513A11,
C81073, FP, SDH2, SDHF
Mm.158231 NM_023281
Sdhb Succinate dehydrogenase complex, subunit B,
iron sulfur (Ip)
0710008N11Rik Mm.246965 NM_023374
Sdhc Succinate dehydrogenase complex, subunit C,
integral membrane protein
0610010E03Rik, AI316496, AU019277, MGC103103 Mm.198138 NM_025321
Sucla2 Succinate-coenzyme A ligase, ADP-forming, beta
subunit
4930547K18Rik Mm.38951 NM_011506
Suclg2 Succinate-coenzyme A ligase, GDP-forming,
beta subunit
AF171077, AW556404, D6Wsu120e, MGC91183 Mm.371585 NM_011507
Tpi1 Triosephosphate isomerase 1 AI255506, Tpi, Tpi-1 Mm.4222 NM_009415
Ugp2 UDP-glucose pyrophosphorylase 2 MGC38262 Mm.28877 NM_139297
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Fig. 1 (See legend on next page.)
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observed a significant reduction in mRNA expression for
the majority of target genes in the skeletal muscle of
SOD1G93A mice when compared to the progressive rise in
gene expression that is normally observed in non-
transgenic wild-type mice during the first 3 months of age
(when muscle growth is occurring [102]). Observations
suggest that metabolic processes that underpin the estab-
lishment of glucose use by muscle in ALS may be compro-
mised, potentially reflecting the disease pathology. Whether
altered expression patterns of glucose and glycogen
metabolism genes are due to the overexpression of the
human SOD1 gene, which itself is proposed to induce
ALS-like pathologies observed in SOD1 mice
[103–106], remains to be determined.
When glucose is not used for energy in the skeletal
muscle, fatty acids [107] and ketones (which are a by-
product of the metabolism of fat) can fuel ongoing
energy demand [108]. Thus, it is not surprising that
observations from SOD1G86R mice identify increased
peripheral clearance of lipids in response to supplemen-
tation with a high-fat diet [53]. Whether these mea-
sures of peripheral lipid clearance reflect an underlying
physiological response to replace atrophic muscle with
fat, fat accumulation due to denervation of muscle
fibres, or fat/ketone transport into muscle for use as an
alternative energy substrate remains unknown. Recent
observations demonstrating an increase in the expression
of genes that are critical in regulating fat metabolism in
the skeletal muscle prior to denervation and improved
endurance exercise performance in SOD1G86R mice are
congruent with the notion that there is a switch in energy
substrate preference in the skeletal muscle from glucose
towards fat [60]. While these data are convincing in pro-
posing that reduced glucose metabolism in the skeletal
muscle contributes to ALS pathophysiology (and reported
fatigue [109]), muscle weakness in ALS is ultimately due
to the loss of innervation from the dying neuron.
Central hypermetabolism and hypometabolism:
implications for neuronal death
A number of in vivo and in vitro studies have investigated
brain or neuronal metabolism to provide insight into how
the metabolic profile of neural cells might be associated
with ALS neuropathology. Brain hypermetabolism has
been observed in bilateral amygdalae, midbrain, pons,
cerebellum, bilateral occipital cortex, globus pallidus, left
inferior temporal cortex, temporal pole, and the hippo-
campus [45, 70, 72]. Given that this hypermetabolism has
been attributed to the local activation of glial cells, it is
likely that neurons in these brain regions are subjected to
an environment that promotes non-cell autonomous
death through the expression of mutant SOD1 [9, 10]
or an α2-Na/K ATPase/α-adducin complex [110] in astro-
cytes. Brain hypometabolism (decreased use of glucose) is
observed in frontal, motor, and occipital cortices, right
insula, anterior and posterior cingulate, precuneus, infer-
ior parietal lobe, caudate, thalamus, putamen, and the left
frontal and superior temporal cortex of ALS patients
[45, 70–72, 111, 112]. In addition, reduced glucose use
has also been reported to occur in the spinal cords of
SOD1G93A mice [113]. Thus, it is plausible that decreased
glucose metabolism leads to an increased dependence on
alternate energy substrates (e.g. ketones that arise from
the oxidation of fat that is mobilized from storage [53])
to fuel survival. It is also feasible that defects in the
capacity for neurons to use glucose as an energy sub-
strate may lead to metabolic deficits that underpin the
death of neurons in ALS. Indeed, decreased production
of energy in the form of ATP and decreased glycolytic
capacity in response to oxidative stress in NSC-34
motoneuron-like cells harbouring the SOD1G93A muta-
tion [114] indicate that impaired neuronal bioenergetics
may play a role in the death of neurons in ALS.
The metabolic demands of the neuron and the
consequences of neuronal ATP depletion
The central nervous system comprises a complex net-
work of highly organized and distinct neural circuits
that mediate interneuronal communication. Energy de-
mand in the brain is high. While accounting for ap-
proximately 2 % of total body mass, the human brain
consumes 20 % of the total oxygen used by the body.
Of the neural cell subtypes in the brain, energy con-
sumption is predominantly demanded by the neurons,
with astrocytes contributing only 5–15 % of the brain
energy requirement [115].
(See figure on previous page.)
Fig. 1 Expression of glucose and glycogen metabolism genes in the skeletal muscle of wild-type and SOD1G93A mice. Compared to non-transgenic
wild-type mice (white bars), the expression of glucose and glycogen metabolism genes in the skeletal muscle of SOD1G93A mice (black bars) does not
increase over the assessed period of muscle growth. Disease stages by age: pre-symptomatic (5 weeks), onset (8 weeks), mid-stage (18 weeks), and
end-stage (24 weeks). Green upward arrows illustrate a significant effect (p < 0.05) of age following analysis by two-way ANOVA. Blue arrows represent
no effect of age (p > 0.05) following analysis by two-way ANOVA. For SOD1G93A mice, relative expression of Phkg1 mRNA declined with age (illustrated
by red downward arrow). The effect of age on gene expression was further interrogated using multiple comparison assessment with Bonferroni post
hoc analysis; *significant differences (p < 0.05) at 8, 18, and 24 weeks of age when compared to 5 weeks of age. An effect of genotype within
each age (5, 8, 18, and 24) was interrogated using multiple comparison assessment with Bonferroni post hoc analysis; #significant (p < 0.05) differences
between WT and SOD1G93A mice at 5, 8, 18, or 24 weeks of age (n = 6 mice/group). Data presented as mean ± SEM. Gene descriptions, symbols,
UniGene identifiers, and NCBI reference sequences (NCBI RefSeq) are provided in Table 1
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Neurons are particularly active cells and, thus, have
high metabolic demand. The metabolic processes in
the neuron consists of (1) submembrane glycolysis,
which is linked to the pumping of ions across the cell
membrane, (2) aerobic glycolysis, which allows for the
generation of pyruvate to fuel aerobic metabolism,
and (3) the production of NADH/ATP in the mito-
chondria by means of the TCA cycle [116]. Although
a low level of basal metabolism is critical for main-
taining the survival of the cell, for active neurons, an
increase in the metabolic demand that is required for
the generation of action potentials [117] and their
large surface area amounts to a considerable metabolic
load that must be met through the generation of ATP.
Neurons are extremely dependent on aerobic metabolism
and oxygen use, but despite a large reservoir of ATP,
reduced glycolytic and/or mitochondrial function modifies
ATP availability, and glucose and oxygen deprivation in
neurons results in cell death [118, 119]. Thus, when
neurons are more active, increased local blood flow and
increased substrate delivery from neighbouring cells is of
critical importance to meet metabolic requirements and
sustain cellular survival. As such, upon activation,
neurons indirectly regulate their own metabolism by re-
leasing by-products (e.g. nitric oxide and glutamate)
that influence the surrounding cells and blood vessels
[120–123]. This leads to the activation of astrocytes
and increased levels of oxygen, lactate and glucose
[117, 124, 125]. Despite categorical evidence that glu-
cose is the chief energy substrate that is used by the
brain to sustain metabolic demand, there is evidence to
suggest that lactate can also be taken up by neurons to
fuel aerobic metabolism [116, 124, 125]; it is postulated
that the neuron-astrocyte lactate shuttle is the structure
that permits the transfer of lactate from astrocytes to
neurons for use as an additional metabolic substrate to
fuel synaptic transmission [126–130]. With lactate be-
ing proposed to be a critical source of energy for active
neurons, the lactate shuttle hypothesis postulates that
neuronal-glutamate released during synaptic transmis-
sion drives aerobic glycolysis in astrocytes. Following
this, glutamate is re-sequestered into astrocytes, result-
ing in the activation of the Na+/K+-ATPase, which in
turn drives the use of cellular ATP. This initiates the
uptake and processing of glucose and, finally, the re-
lease of lactate from astrocytes [127–129]. In line with
a role for the lactate shuttle in the maintenance of
neuronal energy demand, neurons express lactate de-
hydrogenase isoforms that favour the conversion of
lactate to pyruvate and monocarboxylate transport
(MCT2) receptors that take up pyruvate and lactate at
high affinity. Thus, neurons in general, appear appro-
priately equipped to accommodate for their high
metabolic demand [121, 131–134].
In ALS however, a combination of defective energy
metabolism [14, 46], decreased glucose use in the cor-
tex and spinal cord [49, 71, 135, 136], reduced expres-
sion of TCA cycle intermediates in the brain and spinal
cord [137], damaged neuronal mitochondria [138–140],
and mitochondrial electron transport chain dysfunction
[8, 141, 142] suggest that a bioenergetic limitation ex-
ists throughout the course of disease and that the
generation of neuronal ATP is compromised. Moreover,
reduced lactate transport to neurons [119] and im-
paired lactate metabolism and impaired trafficking of
lactate between neurons and astrocytes in SOD1-
related ALS [143] suggest that defects in the lactate
shuttle might further contribute to bioenergetic deficit
in neuronal cells in ALS. Consequently, defects in neur-
onal metabolism may exist regardless of the provision of
alternative energy substrates (e.g. through high calorie
feeding [14, 50, 53, 62, 144] or ketogenic diet [145]) to
sustain or improve neuronal energy supply. In this regard,
treatments that serve to promote or recover the capacity
to sustain cellular energy production will be fundamental
to prevent neuronal death since deficits in the production
of ATP in the presence of escalating metabolic pressures
may underlie the selective and unrelenting death of neu-
rons while exacerbating disease progression during later
stages of ALS. Indeed, the consequences of ATP deficit
has recently been highlighted in a modelling study that
links cellular activity and vulnerability to degeneration to
inadequate levels of cellular energy [146]. In this model, a
deficit in ATP underpins higher metabolic cost to the
neuron. This exacerbates energy deficit and disrupts cellu-
lar ionic gradients, triggering chronic and irreversible de-
polarisation (hyperexcitability) and neuronal death via
ATP depletion [146].
Neuronal hyperexcitability is observed in ALS [11] and
can be defined as an exaggerated response to a stimulus,
which under normal circumstances would elicit an
otherwise standard response. A positive correlation has
been observed between increased axonal hyperexcitabil-
ity [147–149] and disease progression in ALS patients
[148], suggesting that alterations in the membrane excit-
ability of axons that are distal to the neuron cell body
might be central to the disease process. Critically, how-
ever, neuronal hyperexcitability, which may underpin the
degeneration of neurons and their associated connec-
tions in ALS, has been found to occur early in the
course of human ALS [11, 150] and in motor cortex
layer V pyramidal neurons of SOD1G93A mice [151].
The excitability of a neuron and the generation of ac-
tion potentials within neurons are dependent upon cal-
cium (Ca2+), sodium (Na+), and potassium (K+) channels.
Importantly, the opening of voltage-gated K+ channels
evokes the repolarisation of the cell to the resting poten-
tial. This allows the neuron to reduce calcium influx and
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thus decrease synaptic release of glutamate [152]. In light
of a mathematical model proposing that axonal hyperex-
citability in ALS might be due to impaired voltage-gated
K+ currents [148], it has recently been shown that a simi-
lar impairment in voltage-gated K+ currents exists at the
level of the neuron. Retigabine-induced activation of
voltage-gated M-type K+ channels in SOD1 motor neu-
rons derived from ALS patient-induced pluripotent stem
cells (iPSCs) resulted in the reversal of intrinsic mem-
brane hyperexcitability [12]. With evidence demonstrat-
ing that retigabine is also able to extend the survival of
iPSC-derived SOD1 motor neurons from ALS patients,
it is plausible that the activation of other K+ ion chan-
nels that function to attenuate neuronal depolarisation
might produce protective effects in ALS. From an ener-
getic perspective, increased Na+ influx associated with
hyperexcitability in ALS may lead to overloading of the
neuronal Na+-K+ ATPase-dependent pump resulting in
excessive use of cellular ATP, energy failure, and neur-
onal death. Thus, other potential target candidates for
attenuating chronic neuronal depolarisation in ALS
may include K+ channels which couple the metabolic
state of the cell to its activity.
ATP-sensitive potassium (KATP) channels: a new
target in ALS?
KATP channels are octameric protein complexes that are
made up of four pore-forming Kir6 inwardly rectifying po-
tassium channel family (Kir) subunits and four regulatory
sulfonylurea receptor (SUR) subunits [153, 154]. KATP
channels play fundamental roles in cellular physiology. By
regulating the flux of K+ across the cell membrane, KATP
channels link the metabolic state of the cell to its electrical
activity [155]. An increase in energy metabolism (and high
ATP levels) drives the closure of KATP channels, resulting
in membrane depolarization and electrical activity. By con-
trast, in response to metabolic deficit (and low ATP levels),
KATP channels open, thereby driving a suppression in elec-
trical activity [156]. Essentially glucosensing, KATP channels
are regulated by the bioenergetic state of the cell (i.e. intra-
cellular levels of ATP) [156]. Interestingly, KATP channels
are also lactate sensing [157–160], and it has been postu-
lated that they may modulate neuronal excitability in re-
sponse to an increase in cytosolic ATP that is generated
from the oxidation of astrocyte-derived lactate [161].
With mounting evidence to suggest that decreased
cellular ATP production and subsequent alterations in
cellular membrane excitability is associated with neuro-
degenerative disease and neuronal death [146, 162], it
has been proposed that pharmacological mediators of
KATP channels may prove to be promising targets for
alleviating the neurodegenerative processes associated
with disease or with neurotoxic insults [162–164].
However, while KATP channels are widely expressed
[165–169], the biophysical, pharmacological, and meta-
bolic properties of functional KATP channels are dic-
tated by subunit composition [170, 171]. For example,
channels that are formed by Kir6.2 and SUR1 are highly
sensitive to diazoxide and are inhibited by ATP, and
they express biophysical properties that are seen in
pancreatic β cells [172, 173]. Conversely, Kir6.2/SUR2A
KATP channels are somewhat insensitive to diazoxide,
and they are predominantly expressed in the cardiac
and skeletal muscle [171, 174]. Kir6.1/SUR2B or Kir6.2/
SUR2B KATP channels possess properties reminiscent of
those studied in the smooth muscle. While functional
mitochondrial KATP channels have been proposed to be
composed of various subunits [175–177], it is generally
accepted that the molecular identity of such channels is
yet to be determined. Of interest to neurodegeneration
and ALS, Kir6.2/SUR1 KATP channels are widely
expressed on neurons in the brain [168, 169, 178], and
pharmacological targeting of such channels has proven
to be promising in conditions that are associated with
neuronal death.
Diazoxide is a well-known small molecule that acti-
vates KATP channels, including Kir6.2/SUR1 KATP chan-
nels [179]. The neuroprotective effects of diazoxide have
been demonstrated in numerous studies. In cerebral
ischemia-reperfusion injury, diazoxide reduces levels of
reactive oxygen species, decreases DNA oxidative dam-
age, inhibits apoptosis [180–182], and reduces infarct
size during ischemia [183]. In the context of Parkinson’s
disease, diazoxide reduces akinesia [184], protects dopa-
minergic neurons from death by reducing astrocyte and
microglial activation [185], and reduces neuroinflamma-
tion associated with activated microglia [186]. In in vitro
and in vivo models of Alzheimer’s disease, activation of
KATP channels by diazoxide protects against β-amyloid
toxicity, reducing protein aggregation and tau hyper-
phosphorylation [163, 187]. Finally, in addition to hav-
ing been shown to reduce glutamate excitotoxicity in
epilepsy [188], diazoxide also protects NSC-34 moto-
neurons from glutamate-mediated cell death, hydrogen
peroxide-mediated cell death, and inflammatory dam-
age associated with microglial activation, while decreasing
neuronal death in hippocampal slices after N-methyl-D-
aspartic acid (NMDA)-induced excitotoxicity [189].
The use of diazoxide and the investigation of its neu-
roprotective potential and role in ALS however is rela-
tively less well studied. Interestingly, however, a patent
describing oral administration of low doses of diazoxide in
SOD1G93A mice reported improved median values for sur-
vival when compared to non-diazoxide-supplemented
SOD1G93A mice [190]. Whether this improved survival
outcome in diazoxide-supplemented mice is due to the
ability for diazoxide to (a) improve insulin sensitivity and
glucose metabolism (thereby presumably counteracting
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systemic defects in metabolic homeostasis [191]), (b)
cross the blood-brain barrier [192] to counteract intrin-
sic cellular excitability (as has been shown in immature
entorhinal cortex neurons [193]), or (c) counteract
chronic depolarization that might arise from persistent
ATP deficit [146] in response to decreased glucose use
[49, 71, 135, 136] and defective function of the
astrocyte-lactate shuttle in ALS [143] remains to be
determined. Regardless, there is substantial evidence to
suggest that the pharmacological modulation of meta-
bolically sensitive KATP channels by diazoxide (or other
specific activators) represents a promising approach for
obtaining neuroprotection in neurodegenerative dis-
eases, including ALS.
Conclusions and considerations
The debilitating nature of ALS and the lack of effective
treatments against this insidious disease highlight the
need to identify therapeutic targets that are amenable to
therapy. While systemic manifestation of energy deficit
presenting as hypermetabolism, malnutrition, and de-
creased fat stores (due to increased dependence on fat as
an energy substrate) is clearly associated with disease
course, what is more striking is the notion that bioener-
getic deficit (due to decreased ATP production or
decreased glucose metabolism) may contribute in part
to the hyperexcitability and selective degeneration of
upper and lower motor neurons and muscle pathology/
denervation in ALS. When considering all metabolic
components, it may well be that a vicious cycle of bioener-
getic deficit underpins or exacerbates disease pathogenesis
in ALS (Fig. 2). Whether the activation or deactivation of
metabolically sensitive KATP channels and their regulation
of systemic metabolic homeostasis and cellular excitability
ultimately contribute to neuronal hyperexcitability and the
subsequent degeneration of neural networks that are
linked to hyperexcitable cells in ALS remains unknown.
Nonetheless, the potential for KATP channels to be novel
targets for the treatment of ALS is of significance, as the
current availability of a number of compounds that are
selective for KATP channels will greatly facilitate the
pharmacological modulation of KATP channels as an
avenue for future scientific investigation in ALS. The
knowledge that promises to be gained from such studies
will determine whether targeting of metabolic pathways or
accommodation for metabolic dysfunction presents as
promising therapeutic targets in ALS.
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